Resolution Minerals reports three gold holes at Golden Gate North in Idaho, supporting a zone at least 500 metres long ahead ...

Genmab reports 75 per cent first-line response with petosemtamab and chemotherapy; uncontrolled Phase 2 findings include ...

Xencor chose an XmAb819 dose after five of 11 patients responded; severe treatment-related events affected 72.1 per cent ...

Lilly reports a 62% response rate with an olomorasib lung-cancer combination. Randomized SUNRAY-01 results are expected in ...

Ivonescimab plus chemotherapy cut death risk by 25 per cent versus durvalumab plus chemotherapy in a Chinese Phase 3 ...

BioNTech and Bristol Myers report 36.7% confirmed response with pumitamig plus docetaxel in 30 evaluable patients, without a ...

Climb Bio reported immunologic remission in five of 13 pMN patients at 12 weeks. Its uncontrolled Phase 2 trial has more data ...

Canopy Growth shareholders authorized a 1-for-5 to 1-for-15 consolidation on Oct. 23, leaving the ratio and implementation to ...

Genmab will run a Phase 1/2 trial of petosemtamab, Incyte’s KRAS G12D inhibitor and chemotherapy; trial timing and endpoints remain undisclosed.

Google and Voltus announced a 1-gigawatt PJM virtual power plant expansion on Oct. 22, without disclosing a price or delivery schedule.

Teck says Highland Valley Copper is operating at reduced capacity after a strike by USW Local 7619, ahead of Oct. 29 results.

Sterlite reports INR25.29 billion in quarterly revenue and lists a US$1.2 billion hyperscaler supply agreement covering calendar 2026 through 2030.